study we update our findings on more patients with longer logous stem cell transplants for lymphoma in our centre; follow-up. 77/114 (68%) were transplanted after primary therapy. The conditioning regimen varied according to diagnosis; 26 patients were conditioned with melphalan and total body irradiation, 66 shown in Table 1 . The selection criteria for transplantation in
Introduction
Patients who had ABMT in CR1 were chosen for early intensiIntensive chemotherapy followed by autologous stem cell resfication because of poor prognostic features at diagnosis.
15
cue (ABMT) is used with increasing frequency in the treatment Since 1991 these patients have all been included in a prospecof leukaemias, lymphomas and solid tumours. As transplanttive, randomised controlled trial. Treatment pre-transplant related mortality decreases, the trend for more patients to be comprised three courses of a 4 week, eight drug schedule: offered ABMT in first complete remission has become apparvinblastine, etoposide, adriamycin, vincristine, procarbazine, ent. Many of these patients will hopefully survive disease free chlorambucil, adriamycin, bleomycin and prednisolone for long periods of time; it is therefore essential to assess con-(PVACE-BOP) ± radiotherapy to site of bulk disease. All tinually the long-term toxicities of the transplant procedure.
patients were conditioned with the melphalan and etoposide Secondary malignancy has long been recognised as an regimen (see Table 2 ). important late complication of the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).
1-4 Several recent studies [5] [6] [7] [8] [9] [10] [11] [12] [13] have reported the occurrence of myeloNon-Hodgkin's lymphoma (NHL) dysplastic syndrome and secondary acute myeloid leukaemia in patients following ABMT with incidences ranging from 4 to Forty-seven patients with Kiel high-grade NHL were trans-14%. Whether these are related to the chemotherapy given planted in CR1. Patients were selected for ABMT in first compre-transplant or the myeloablative therapy given at the time plete remission in the early years because of the presence of of transplant is unclear, as in most reported studies the poor prognostic features, such as lymphoblastic histology.
16 majority of patients have been treated for multiple relapses Since 1991, patients have been treated as part of randomised prior to transplant. trials and have been selected using prognostic indices.
17,18
In our centre we have been performing ABMT, predomiConditioning for NHL varied: all patients received melphalan. nantly in first complete remission (CR1), for over 10 years. We Eighteen were given TBI in addition because they were perhave reviewed all our transplant patients annually to assess ceived to be at risk of central nervous system relapse (eg Burkthe incidence of complications post-transplantation. Initial itt's or other lymphoblastic histology). Ten received etoposide findings on our incidence of secondary haematological probin addition to melphalan as part of a randomised trial. Primary lems were published as a letter 14 This patient has been reported previously. Prior to transplant, all patients had their marrows checked to and following relapse she was given a further six courses. At assess cellularity and confirm morphological haematological second relapse the following year she received treatment with remission. Cytogenetic studies on marrow were not routinely an intensive regimen IVE 19 and then proceeded to transplant obtained immediately pre-transplant. using melphalan/etoposide as conditioning. Twenty months Patients were given a minimum of 2 × 10 8 /kg non-cryoprepost-transplant she developed acute myeloid leukaemia, M2, served cells as rescue. In eight patients, sufficient cells were with a trisomy 11. not available from the first harvest; this was cryopreserved and an additional harvest performed 1 month later. Two were transplanted using PBSC collection alone and a further patient Discussion had PBSC and fresh marrow.
In order that physicians can counsel their patients appropriately it is important to elucidate whether the MDS/secondary Conditioning regimens leukaemias observed post-autologous stem cell transplant are really complications of the transplant procedure (ie of the conPatients were given one of three conditioning regimens depending on their disease (see Table 2 ). Because we usually ditioning regimen) or a consequence of prior chemotherapy. Our centre has been performing autotransplants for more rescue with fresh marrow only, cytotoxic drugs with a short plasma half-life were selected for conditioning. than 10 years. The majority of our patients have been transplanted in first remission, therefore providing useful data to assess the additional long-term toxicities of the transplant procedure without the confounding influence of repeated courses Survival analysis of potentially leukaemogenic treatment. From a series of 114 patients (the census population) 69 (60%) were transplanted Survival was calculated from date of transplant using the Kaplan-Meier method. 20 Status was taken from the date the after primary therapy and received no further treatment posttransplant. With a median follow-up of 62 months we patient was last known to be alive.
observed only two cases of new haematological malignancy post-transplant. The first was the rapid onset of chronic granulocytic leukaemia. On balance we consider that the CGL Results observed in this patient was a true de novo malignancy rather than a secondary phenomenon and we have argued this elseOne hundred and fourteen patients have undergone an autologous stem cell transplant. Bone marrow was used as the sole where. 21 The second patient developed AML with trisomy 11, 20 months post-transplant. Unusually for our patients, she had source of stem cells in all but three patients.
With a median follow-up of 62 months, we have observed been transplanted in third complete remission and had received a total of 14 courses of chemotherapy pre-transplant. only two cases of haematological malignancy post-transplant in our patients. Both patients had been treated for Hodgkin's This leukaemia probably represents a true secondary malignancy, and it seems likely that the previous chemotherapy was disease. an important factor in its aetiology. Our incidence of secondfor malignancy alone; in the four studies where data are available 5-7,10 the time to development of the secondary maligary leukaemia is therefore 1.1% (95% CI 0.02-4.96). While it is not statistically significant, it is worth noting that none of nancy from diagnosis (6-7 years) is seen to be identical to that observed in patients who have only had multiple courses of the 69 patients who received primary therapy and transplant with no further treatment developed a haematological probconventional chemotherapy for relapsed/resistant disease. We do not routinely assess the marrow of our patients postlem, whereas in the other 45 patients who received multiple courses of treatment there has been one case of a true secondtransplant to look for evidence of myelodysplasia/ haematological malignancy, either morphologically or cytoary malignancy.
The risk of developing a secondary haematological maliggenetically. It is, therefore, possible that some patients may yet develop such a malignancy, and we therefore consider it nancy at 5 years in our series is 1.1% (95% CI 0.02-4.96) which is lower than that in most reported series (see Table 3 ).
essential that all transplant patients are followed-up long-term in a dedicated clinic so that such problems are not underOur patients differ in three respects:
reported. (1) We have performed the majority (60%) of our transplants
In conclusion, the occurrence of a second malignancy as in first remission, ie after primary treatment. The cumulata result of attempts to cure the primary one is a devastating ive dose of chemotherapy is therefore less in our series complication of treatment for patient and physician. Because than in most others.
of the success of ABMT as a salvage therapy, it is now increas-(2) In all but 11 patients we used fresh, unmanipulated maringly offered to patients after primary treatment. When row as the only source of stem cell rescue.
patients are asked to give consent to such procedures it is (3) Only three patients were rescued using stem cells harimportant that both the short-term and long-term risks of the vested from peripheral blood (in two patients this was the procedure are explained. We consider that our data, which only source). demonstrate a very low level of secondary haematological malignancy in a census population with a median follow-up We know of no data to suggest that the freeze-thaw procedure of more than 5 years, lend weight to the hypothesis that it is involved in cryopreservation in itself can produce mutations the treatment given prior to conditioning for the transplant, in harvested stem cells. However, there are three published rather than the myeloablative conditioning itself, which is studies which suggest that there is an increased risk of responsible for the development of MDS/AML in these MDS/secondary leukaemia following PBSC transplant. In one patients. Whether the increased incidence of MDS/leukaemia study 5 involving 206 patients, the projected incidence of MDS following PBSC rescue reflects some effect of the harvesting was 31% in patients receiving PBSC vs 10% if bone marrow procedure itself requires further study. cells were used (P = 0.0035). In a second study 10 on 275 patients, an increased risk which does not quite reach statistical significance was observed with the use of PBSC as support (P = 0.07; relative risk 0.28) and in a recent review of the inciReferences dence of second cancers in 467 patients transplanted for HD 13 1 Levine EG, Bloomfield CD. Leukemias and myelodysplastic synone of the factors noted to increase the risk was PBSC dromes secondary to drug, radiation, and environmental exposure (P = 0.038). Preferential use of PBSC in more intensively pre- is similar to that reported for patients who have been treated
